These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37499679)

  • 1. Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial.
    Sagara I; Healy SA; Assadou MH; Kone M; Swihart BJ; Kwan JL; Fintzi J; Sissoko K; Kamate B; Samake Y; Guindo MA; Doucoure M; Niaré K; Dolo A; Diarra B; Rausch KM; Narum DL; Jones DS; MacDonald NJ; Zhu D; Gorres JP; Imeru A; Mohan R; Thera I; Zaidi I; Salazar-Miralles F; Duan J; Neal J; Morrison RD; Muratova O; Sylla D; O'Connell EM; Wu Y; Hume JCC; Coulibaly MB; Anderson CF; Traore SF; Doumbo OK; Duffy PE
    Lancet Infect Dis; 2023 Nov; 23(11):1266-1279. PubMed ID: 37499679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults.
    Sagara I; Healy SA; Assadou MH; Gabriel EE; Kone M; Sissoko K; Tembine I; Guindo MA; Doucoure M; Niaré K; Dolo A; Rausch KM; Narum DL; Jones DL; MacDonald NJ; Zhu D; Mohan R; Muratova O; Baber I; Coulibaly MB; Fay MP; Anderson C; Wu Y; Traore SF; Doumbo OK; Duffy PE
    Lancet Infect Dis; 2018 Sep; 18(9):969-982. PubMed ID: 30061051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice.
    Healy SA; Anderson C; Swihart BJ; Mwakingwe A; Gabriel EE; Decederfelt H; Hobbs CV; Rausch KM; Zhu D; Muratova O; Herrera R; Scaria PV; MacDonald NJ; Lambert LE; Zaidi I; Coelho CH; Renn JP; Wu Y; Narum DL; Duffy PE
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33561016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial.
    Sissoko MS; Healy SA; Katile A; Zaidi I; Hu Z; Kamate B; Samake Y; Sissoko K; Mwakingwe-Omari A; Lane J; Imeru A; Mohan R; Thera I; Guindo CO; Dolo A; Niare K; Koïta F; Niangaly A; Rausch KM; Zeguime A; Guindo MA; Bah A; Abebe Y; James ER; Manoj A; Murshedkar T; Kc N; Sim BKL; Billingsley PF; Richie TL; Hoffman SL; Doumbo O; Duffy PE
    Lancet Infect Dis; 2022 Mar; 22(3):377-389. PubMed ID: 34801112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.
    Talaat KR; Ellis RD; Hurd J; Hentrich A; Gabriel E; Hynes NA; Rausch KM; Zhu D; Muratova O; Herrera R; Anderson C; Jones D; Aebig J; Brockley S; MacDonald NJ; Wang X; Fay MP; Healy SA; Durbin AP; Narum DL; Wu Y; Duffy PE
    PLoS One; 2016; 11(10):e0163144. PubMed ID: 27749907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.
    Sirima SB; Richert L; Chêne A; Konate AT; Campion C; Dechavanne S; Semblat JP; Benhamouda N; Bahuaud M; Loulergue P; Ouédraogo A; Nébié I; Kabore M; Kargougou D; Barry A; Ouattara SM; Boilet V; Allais F; Roguet G; Havelange N; Lopez-Perez E; Kuppers A; Konaté E; Roussillon C; Kanté M; Belarbi L; Diarra A; Henry N; Soulama I; Ouédraogo A; Esperou H; Leroy O; Batteux F; Tartour E; Viebig NK; Thiebaut R; Launay O; Gamain B
    Lancet Infect Dis; 2020 May; 20(5):585-597. PubMed ID: 32032566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission.
    Rausch KM; Barnafo EK; Lambert LE; Muratova O; Gorres JP; Anderson C; Narum DL; Wu Y; Morrison RD; Zaidi I; Duffy PE
    iScience; 2023 Jul; 26(7):107192. PubMed ID: 37485364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice.
    Coelho CH; Gazzinelli-Guimaraes PH; Howard J; Barnafo E; Alani NAH; Muratova O; McCormack A; Kelnhofer E; Urban JF; Narum DL; Anderson C; Langhorne J; Nutman TB; Duffy PE
    Vaccine; 2019 Feb; 37(8):1038-1045. PubMed ID: 30685251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.
    Chichester JA; Green BJ; Jones RM; Shoji Y; Miura K; Long CA; Lee CK; Ockenhouse CF; Morin MJ; Streatfield SJ; Yusibov V
    Vaccine; 2018 Sep; 36(39):5865-5871. PubMed ID: 30126674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial.
    Adegnika AA; de Vries SG; Zinsou FJ; Honkepehedji YJ; Dejon Agobé JC; Vodonou KG; Bikangui R; Bouyoukou Hounkpatin A; Bache EB; Massinga Loembe M; van Leeuwen R; Molemans M; Kremsner PG; Yazdanbakhsh M; Hotez PJ; Bottazzi ME; Li G; Bethony JM; Diemert DJ; Grobusch MP;
    Lancet Infect Dis; 2021 Feb; 21(2):275-285. PubMed ID: 32926834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
    Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.
    Shimp RL; Rowe C; Reiter K; Chen B; Nguyen V; Aebig J; Rausch KM; Kumar K; Wu Y; Jin AJ; Jones DS; Narum DL
    Vaccine; 2013 Jun; 31(28):2954-62. PubMed ID: 23623858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial.
    Sissoko MS; Healy SA; Katile A; Omaswa F; Zaidi I; Gabriel EE; Kamate B; Samake Y; Guindo MA; Dolo A; Niangaly A; Niaré K; Zeguime A; Sissoko K; Diallo H; Thera I; Ding K; Fay MP; O'Connell EM; Nutman TB; Wong-Madden S; Murshedkar T; Ruben AJ; Li M; Abebe Y; Manoj A; Gunasekera A; Chakravarty S; Sim BKL; Billingsley PF; James ER; Walther M; Richie TL; Hoffman SL; Doumbo O; Duffy PE
    Lancet Infect Dis; 2017 May; 17(5):498-509. PubMed ID: 28216244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Diawara H; Healy SA; Mwakingwe-Omari A; Issiaka D; Diallo A; Traore S; Soumbounou IH; Gaoussou S; Zaidi I; Mahamar A; Attaher O; Fried M; Wylie BJ; Mohan R; Doan V; Doritchamou JYA; Dolo A; Morrison RD; Wang J; Hu Z; Rausch KM; Zeguime A; Murshedkar T; Kc N; Sim BKL; Billingsley PF; Richie TL; Hoffman SL; Dicko A; Duffy PE;
    Lancet Infect Dis; 2024 Dec; 24(12):1366-1382. PubMed ID: 39153490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial.
    Silk SE; Kalinga WF; Salkeld J; Mtaka IM; Ahmed S; Milando F; Diouf A; Bundi CK; Balige N; Hassan O; Mkindi CG; Rwezaula S; Athumani T; Mswata S; Lilolime NS; Simon B; Msami H; Mohamed M; David DM; Mohammed L; Nyaulingo G; Mwalimu B; Juma O; Mwamlima TG; Sasamalo IA; Mkumbange RP; Kamage JJ; Barrett JR; King LDW; Hou MM; Pulido D; Carnrot C; Lawrie AM; Cowan RE; Nugent FL; Roberts R; Cho JS; Long CA; Nielsen CM; Miura K; Draper SJ; Olotu AI; Minassian AM
    Lancet Infect Dis; 2024 Oct; 24(10):1105-1117. PubMed ID: 38880111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
    Datoo MS; Natama MH; Somé A; Traoré O; Rouamba T; Bellamy D; Yameogo P; Valia D; Tegneri M; Ouedraogo F; Soma R; Sawadogo S; Sorgho F; Derra K; Rouamba E; Orindi B; Ramos Lopez F; Flaxman A; Cappuccini F; Kailath R; Elias S; Mukhopadhyay E; Noe A; Cairns M; Lawrie A; Roberts R; Valéa I; Sorgho H; Williams N; Glenn G; Fries L; Reimer J; Ewer KJ; Shaligram U; Hill AVS; Tinto H
    Lancet; 2021 May; 397(10287):1809-1818. PubMed ID: 33964223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial.
    Tapia MD; Sow SO; Lyke KE; Haidara FC; Diallo F; Doumbia M; Traore A; Coulibaly F; Kodio M; Onwuchekwa U; Sztein MB; Wahid R; Campbell JD; Kieny MP; Moorthy V; Imoukhuede EB; Rampling T; Roman F; De Ryck I; Bellamy AR; Dally L; Mbaya OT; Ploquin A; Zhou Y; Stanley DA; Bailer R; Koup RA; Roederer M; Ledgerwood J; Hill AVS; Ballou WR; Sullivan N; Graham B; Levine MM
    Lancet Infect Dis; 2016 Jan; 16(1):31-42. PubMed ID: 26546548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
    Platt H; Omole T; Cardona J; Fraser NJ; Mularski RA; Andrews C; Daboul N; Gallagher N; Sapre A; Li J; Polis A; Fernsler D; Tamms G; Xu W; Murphy R; Skinner J; Joyce J; Musey L
    Lancet Infect Dis; 2023 Feb; 23(2):233-246. PubMed ID: 36116461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.
    Wu Y; Ellis RD; Shaffer D; Fontes E; Malkin EM; Mahanty S; Fay MP; Narum D; Rausch K; Miles AP; Aebig J; Orcutt A; Muratova O; Song G; Lambert L; Zhu D; Miura K; Long C; Saul A; Miller LH; Durbin AP
    PLoS One; 2008 Jul; 3(7):e2636. PubMed ID: 18612426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Pfs48/45-based vaccine to block Plasmodium falciparum transmission: phase 1, open-label, clinical trial.
    Alkema M; Smit MJ; Marin-Mogollon C; Totté K; Teelen K; van Gemert GJ; van de Vegte-Bolmer M; Mordmüller BG; Reimer JM; Lövgren-Bengtsson KL; Sauerwein RW; Bousema T; Plieskatt J; Theisen M; Jore MM; McCall MBB
    BMC Med; 2024 Apr; 22(1):170. PubMed ID: 38649867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.